Can GLP-1 medicines help women with polycystic ovary syndrome become pregnant? A new evidence review leaves that question unresolved. Its clearest signal concerns metabolic improvement; changes in hormones and menstrual cycles are less consistent. Those outcomes matter, but they do not answer the same question as pregnancy or live birth.
The systematic review published online on October 30, 2026 examined adult women with insulin resistance and excess androgens, including PCOS and the rarer, severe HAIR-AN syndrome. It combined evidence from randomized trials, observational studies and case series. Looking at two original studies it cites shows why a promising weight-management result needs careful translation into reproductive-health claims.
What the new review can tell us
The authors describe metabolic responses as more consistent than endocrine responses and report variable menstrual outcomes. Their abstract does not provide the number of included studies, a pooled effect estimate or enough methodological detail to assess how individual studies were weighted. We inspected that abstract, rather than the review’s full paper or supplement, so this article does not assign a numerical fertility benefit to the review.
That limitation also matters for HAIR-AN, which the review describes as having limited evidence. Findings in one PCOS population cannot automatically describe every woman with androgen excess or a more severe insulin-resistant condition.
A randomized trial asked about weight and androgens
In a 2022 placebo-controlled trial, 82 women with PCOS and obesity were randomized to liraglutide or placebo alongside lifestyle intervention. The research regimen was 3 mg daily for 32 weeks; this describes the study, not a dosing recommendation. The published abstract reports average weight changes of −5.7% with liraglutide and −1.4% with placebo, and an improvement in the free androgen index, a measure calculated from hormone concentrations.
These are encouraging findings within a controlled experiment. They also came with tolerability costs: gastrointestinal events were reported in 58.2% of liraglutide recipients and 18.5% of placebo recipients, mostly mild to moderate. The abstract does not fully describe the missing-data analysis, so the weight figures should not be treated as a guaranteed result for every person starting treatment.
The trial registration clarifies the reproductive question. Its primary outcomes were body weight and free androgen index, with menstrual frequency among the secondary outcomes. Participants with diabetes were excluded, effective contraception was required, and women wanting pregnancy within the next 15 months were excluded. This design could investigate metabolic and hormonal changes; it was not designed to demonstrate improved chances of pregnancy.
Why a small semaglutide study needs a different reading
A 2023 semaglutide study followed 27 women with obesity and PCOS who had not achieved the study’s weight-loss threshold during an earlier lifestyle program. None had type 2 diabetes. All had the same PCOS phenotype, involving androgen excess, disrupted ovulation and polycystic ovarian morphology. They received 0.5 mg weekly as the research regimen.
There was no randomized drug-treatment comparator. After three months, only the 21 women who had lost more than 5% of their starting weight continued treatment for another three months. The later findings therefore describe selected initial responders, not everyone who began treatment. Although the paper also describes healthy controls, those women provided baseline comparisons, not a randomized test of treatment.
Menstrual improvement was reported, but it cannot establish a live-birth benefit. Nor can this small, selected cohort establish that semaglutide is better than liraglutide for PCOS. Different designs, durations and participant selection prevent that ranking. Our semaglutide profile gives broader drug context, while the guide to randomized and observational evidence explains what a comparison group contributes.
Separate the treatment goal from the headline
The 2023 international PCOS guideline allows consideration of anti-obesity medicines, including GLP-1 receptor agonists, for higher weight in adults with PCOS alongside lifestyle support and according to general population guidance. It also highlights side effects, potential long-term treatment needs and weight regain after stopping. That is a weight-management discussion, not proof that these medicines improve fertility.
The same guideline emphasizes effective contraception when pregnancy is possible because pregnancy safety data are lacking. Our pregnancy and weight-loss medication guide explains why planning a pregnancy needs a separate discussion with the treating clinician. This review does not supply a treatment-switching or pregnancy-timing plan.
For a clinical conversation, useful questions are: which outcome is treatment intended to improve; how will that outcome be assessed; and how do reproductive plans affect the options? For the next study headline, look for actual pregnancy or live-birth outcomes, an appropriate comparator and follow-up of everyone assigned treatment. The trial-reading guide offers a framework. Better weight or hormone measurements can be valuable without resolving a different outcome that has not been adequately tested.



